01-671-944
Neisseria gonorrhoeae Monoclonal Antibody (GC12-316.4), Invitrogen™
Manufacturer: Fischer Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | 01-671-944-Each-of-1 | In Stock | ₹ 49,884.50 |
01-671-944 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 49,884.50
GST (18%): ₹ 8,979.21
Total Price: ₹ 58,863.71
Antigen
Neisseria gonorrhoeae
Classification
Monoclonal
Concentration
0.7 mg/mL
Formulation
PBS with no preservative; pH 7.4
Host Species
Mouse
Purification Method
Protein A
Regulatory Status
RUO
Target Species
Bacteria
Product Type
Antibody
Isotype
IgG3
Applications
ELISA
Clone
GC12-316.4
Conjugate
Unconjugated
Gene Alias
Gonococci; N. gonorrhoeae
Immunogen
UV-inactivated Neisseria gonorrhoeae cells W-I, W-II, W-III.
Quantity
500 μg
Primary or Secondary
Primary
Content And Storage
-20° C, Avoid Freeze/Thaw Cycles
Form
Liquid
Related Products
Description
- MA1-10714 detects Neisseria gonorrhoeae
- MA1-10714 has been successfully used in ELISA applications
- The MA1-10714 immunogen is UV-inactivated Neisseria gonorrhoeae cells W-I, W-II, W-III
- Although pathogenic bacteria constitute only a small portion of bacterial species, infectious diseases caused by pathogenic bacteria affect millions of people worldwide
- Diarrheal diseases, many of which are bacterial, are the second leading cause of death worldwide, claiming an estimated 5 million people annually
- Furthermore, an estimated 3 million people die of tuberculosis annually, 500,000 people die of pertussis, and 25,000 die of typhoid
- The ability of bacteria to utilize various food sources is a major factor behind their pervasiveness
- Their vast numbers lead to rapid evolutionary changes resulting in emerging diseases as well as antibiotic-resistant strains of well known diseases
- Examples of these are multi-drug resistant tuberculosis and methicillin-resistant Staphylococcus aureus
- Research into the detection and treatment of these infectious disease agents will continue to expand in an effort to alleviate the effects of these diseases.